Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 15 articles: HTML format

Single Articles

April 2025
1. TANAKA Y, Ono R, Ashiarai M, Sakurai A, et al
   The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia.
   Cancer Chemother Pharmacol. 2025;95:50.
   PubMed     Abstract available
   
   
   February 2025
2. DARSTEIN C, Yoon D, Yang Y, Kapoor S, et al
   Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.
   Cancer Chemother Pharmacol. 2025;95:39.
   PubMed     Abstract available
   
   
   
3. OUERDANI A, Valenzuela B, Treijtel N, Haddish-Berhane N, et al
   Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
   Cancer Chemother Pharmacol. 2025;95:38.
   PubMed     Abstract available
   
   
   
4. CAO A, Guan Y, Wang J, Li X, et al
   Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship.
   Cancer Chemother Pharmacol. 2025;95:33.
   PubMed     Abstract available
   
   
   January 2025
5. MAHER KR, Shafer D, Schaar D, Bandyopadhyay D, et al
   A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
   Cancer Chemother Pharmacol. 2025;95:24.
   PubMed     Abstract available
   
   
   December 2024
6. MANGOURA SA, Abdel-Raheem MH, Eltyb HA, Molla MS, et al
   Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
   Cancer Chemother Pharmacol. 2024;95:12.
   PubMed     Abstract available
   
   
   
7. MATSUI M, Yasu T, Makimoto A, Yuza Y, et al
   Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).
   Cancer Chemother Pharmacol. 2024;95:1.
   PubMed     Abstract available
   
   
   September 2024
8. CHRISTENSEN SR, Jensen CF, Heldrup J, Taylor Z, et al
   Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination.
   Cancer Chemother Pharmacol. 2024 Sep 21. doi: 10.1007/s00280-024-04713.
   PubMed     Abstract available
   
   
   July 2024
9. RAHMAYANTI SU, Amalia R, Rusdiana T
   Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.
   Cancer Chemother Pharmacol. 2024 Jul 13. doi: 10.1007/s00280-024-04694.
   PubMed     Abstract available
   
   
   June 2024
10. CEREJA-PANTOJA KBC, de Brito Azevedo TC, Vinagre LWMS, de Moraes FCA, et al
    Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.
    Cancer Chemother Pharmacol. 2024 Jun 18. doi: 10.1007/s00280-024-04689.
    PubMed     Abstract available
    
    
    
11. GAIETTO A, Panetta JC, Pauley JL, Relling MV, et al
    Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.
    Cancer Chemother Pharmacol. 2024;93:617-625.
    PubMed     Abstract available
    
    
    May 2024
12. KOBAYASHI T, Sato H, Miura M, Fukushi Y, et al
    Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 May 23. doi: 10.1007/s00280-024-04673.
    PubMed     Abstract available
    
    
    March 2024
13. DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al
    Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
    Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644.
    PubMed     Abstract available
    
    
    
14. QU W, Lu J, Ji Y, He Z, et al
    Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642.
    PubMed     Abstract available
    
    
    February 2024
15. MARCELLETTI JF, Sikic BI
    Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
    Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.